Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Invivyd, Inc. (Nasdaq: IVVD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Invivyd is a Delaware-incorporated biopharmaceutical company whose common stock is listed on The Nasdaq Stock Market LLC under the symbol IVVD, as noted in multiple Form 8-K reports.
Through this page, readers can review Invivyd’s current and historical Form 8-K filings, which describe material events such as public offerings of common stock and pre-funded warrants, entry into underwriting agreements, clinical and regulatory milestones for its monoclonal antibody programs, and corporate governance changes. Examples include 8-Ks detailing underwritten offerings to fund commercial preparedness for VYD2311, research and development for RSV and measles programs, and formation of the SPEAR Study Group to study monoclonal antibody therapy for Long COVID and COVID-19 post-vaccination syndrome.
Invivyd’s filings also reference press releases on topics such as U.S. IND clearance and FDA alignment on the pivotal clinical program for VYD2311, Fast Track designation for VYD2311, selection of the RSV antibody candidate VBY329, and financial results for recent quarters. Other 8-Ks note Nasdaq correspondence regarding the company’s compliance with minimum bid price requirements and confirm that the matter was resolved after the company regained compliance.
On Stock Titan, Invivyd filings are updated as they appear on EDGAR, and AI-powered tools summarize key points from each document. Users can quickly identify why a filing was made, what agreements or clinical developments it describes, and how it relates to Invivyd’s antibody pipeline, EUA-authorized PEMGARDA product, and capital-raising activities. This helps investors and researchers navigate lengthy regulatory documents and focus on the disclosures most relevant to IVVD’s business and stock.
Invivyd, Inc. (IVVD) filed a Form 144 notifying a proposed sale of 36,631 shares of Common Stock on or about 08/18/2025 through Morgan Stanley Smith Barney LLC on Nasdaq, with an aggregate market value of $25,901.78. The securities were acquired on 08/15/2025 upon vesting of restricted stock units granted under the issuer's 2021 Equity Incentive Plan and payment was recorded as Equity Compensation. The filer reports “Nothing to Report” for securities sold during the past three months. Several identifying filer fields in the filing (CIK, contact name, phone, email, and issuer name/address) are not provided in the supplied content.
Invivyd, Inc. (IVVD) filed a Form 144 reporting a proposed sale of 39,600 shares of common stock on 08/18/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $28,001.16. The shares were acquired on 08/15/2025 upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan; 99,000 shares were acquired upon vesting and payment was by equity compensation on 08/15/2025. The filing shows 120,142,811 shares outstanding and indicates no reported sales by the seller in the past three months.
Form 144 notice for Invivyd, Inc. (IVVD) indicates a proposed sale of 39,601 shares of common stock on or about 08/18/2025 through Morgan Stanley Smith Barney LLC on the Nasdaq, with an aggregate market value reported as $28,001.87. The shares were acquired upon vesting of restricted stock units under the issuer's 2021 Equity Incentive Plan and were recorded as acquired and paid on 08/15/2025. The filer reports no securities sold in the past three months. Several identifying fields in the filing (filer CIK, contact details, issuer name and person for whose account the sale is to be made) are not populated in the provided content.
Invivyd, Inc. reported operational and financing disclosures in its Form 10-Q, including capital structure, third-party agreements and program cost changes. The company noted Emergency Use Authorization for PEMGARDA in March 2024 and that sales of PEMGARDA have funded operations. During the period the company sold 9,000,000 shares under an at-the-market facility for net proceeds of $39.3 million at an average price of $4.50 per share and had $325 million of securities remaining on its shelf registration as of June 30, 2025. A $30 million Term Facility is available in three tranches subject to financial covenants and net product revenue milestones; as of June 30, 2025 the company had not met the revenue milestone required to draw on the earliest tranche. Material contractual items include significant Adimab obligations (quarterly fees of $0.6 million and royalty terms, including 45%–55% on certain compulsory sublicenses), lease liabilities of $1.1 million (current) and $1.9 million (non-current), and stock plans and equity awards including 1,700,000 RSUs granted at $1.61 per share.
Invivyd, Inc. filed a current report describing several disclosures made on August 14, 2025. The company issued a press release with its financial results for the quarter ended June 30, 2025 and recent business highlights, which is included as Exhibit 99.1.
Invivyd also released a separate press release titled “Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19,” filed as Exhibit 99.2. In addition, the company posted an updated corporate presentation on its website, furnished as Exhibit 99.3.
This Schedule 13G/A discloses that Maverick Capital, Ltd., Maverick Capital Management, LLC and Lee S. Ainslie III report beneficial ownership of 10,229,118 shares of Invivyd, Inc., representing 8.5% of the 119,961,445 outstanding shares reported as of May 1, 2025. The filing identifies the shares as held for Maverick clients across five funds: Maverick Fund USA, Ltd. (2,253,369), Maverick Fund II, Ltd. (2,210,410), Maverick Long Enhanced Fund, Ltd. (2,419,202), Maverick HP, L.P. (2,139,246) and Maverick Long Fund, Ltd. (1,206,891).
Each reporting person states shared voting and dispositive power over these shares and no sole voting or dispositive power. The document is filed as a Schedule 13G (Amendment No. 2) and includes a certification that the securities were not acquired to change or influence control of the issuer. The filing lists Maverick's Dallas, TX address and Mr. Ainslie's West Palm Beach, FL address and is signed on 08/14/2025.
Invivyd, Inc. (Nasdaq: IVVD) filed an 8-K to disclose that, on July 2, 2025, it issued a press release announcing the formation of the SPEAR (Spike Protein Elimination and Recovery) Study Group. The collaboration brings Invivyd together with leading researchers to evaluate the effects of the company’s monoclonal antibody therapy on two patient populations: 1) individuals suffering from Long COVID and 2) those experiencing COVID-19 post-vaccination syndrome.
The filing contains no financial results, trial data, or guidance. Instead, it simply furnishes the press release as Exhibit 99.1 under Item 8.01 (Other Events) and lists customary exhibit and signature information.
Invivyd (Nasdaq: IVVD) filed an 8-K under Item 8.01 to furnish a press release dated 26 June 2025.
The release reports positive full Phase 1/2 clinical data for VYD2311, a next-generation COVID-19 monoclonal antibody being pursued for both non-vaccine prophylaxis and treatment of active infection.
The document attaches the press release as Exhibit 99.1; no financial statements, guidance changes, or other material corporate actions were disclosed.